The majority of the CDKN1B and CCND2 genotypes demonstrated by us as determining a progressive CLL course (e.g., CDKN1Brs36228499CC, CDKN1Brs2066827TT, CCND2rs3217901AG, CCND2rs3217810T) were previously described as predictors for the risk of uncontrolled proliferation in solid tumors [46,49,63,68,74], and their prevalence in aggressive CLL could be associated with the enhanced proliferative potential of the circulating lymphocytes. This evidence concerns the gene CCND2 and B-cell chronic lymphocytic leukemia.